Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Gonadorelin peptide icon, one bubble per amino acidGonadorelin10 residuesQHWSYGLRPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Gonadorelin

Beginner tier: 100 mcg, 2x/week · community consensus

Sexual HealthFDA Approved
2-4 min half-life·Injection

Also known as: GnRH, LHRH, Factrel

Ten amino acids. That's all gonadorelin is, a synthetic copy of the GnRH your hypothalamus fires every 60 to 120 minutes to keep testosterone and fertility running. The FDA approved it back in 1982 as Factrel for pituitary diagnostics. A 2025 retrospective cohort study (n=155)[1] found pulsatile GnRH triggered spermatogenesis in 82.1% of men with congenital hypogonadotropic hypogonadism (CHH). Today it's the go-to HCG alternative for men on TRT who want to keep their testes functioning and their fertility intact, especially after the 2020 HCG compounding ban made brand HCG cost-prohibitive.

What Is Gonadorelin?

82.1% spermatogenesis rate. That's what a 2025 retrospective cohort study (n=155)[1] found with pulsatile gonadorelin delivered via pump in men with congenital hypogonadotropic hypogonadism. Men on hCG/HMG hit 75.8%, and the gap was not statistically significant.

Gonadorelin (also called GnRH, LHRH, or gonadorelin acetate/hydrochloride; CAS 33515-09-2) is the synthetic version of gonadotropin-releasing hormone. Your hypothalamus naturally pulses this 10-amino-acid peptide roughly every 90 minutes. Each pulse tells pituitary gonadotroph cells to release LH and FSH, which then signal the testes to produce testosterone and sperm.

The mechanism is straightforward but timing-dependent. Pulsatile stimulation keeps GnRH receptors responsive. Constant exposure does the opposite: receptors internalize and LH/FSH production shuts down. This is actually how leuprolide suppresses testosterone in prostate cancer patients. So with gonadorelin, how often you inject matters more than how much you inject.

Since the 2020 HCG compounding ban, gonadorelin has become the most widely prescribed HCG alternative at TRT clinics across the US. Community data from over 500 Reddit threads and TRT clinic protocols tells a consistent story: the standard 2x/week clinic prescription usually disappoints, while nightly 100 mcg protocols produce more reliable testicular preservation. Compounded pricing runs $15 to $35 per month, a fraction of brand HCG. Gonadorelin is not on FDA's 503A bulk drug substance category lists (updated May 14, 2026), and licensed compounding pharmacies prepare it with a prescription.

How Gonadorelin Works

Gonadorelin binds to GnRH receptors on gonadotroph cells in the anterior pituitary. Those receptors are Gq/11-coupled. Activation triggers phospholipase C, which raises intracellular calcium and opens the gates for LH and FSH secretion into the bloodstream.

LH travels to Leydig cells in the testes and drives testosterone production. FSH targets Sertoli cells, which support spermatogenesis. Both hormones are required for full testicular function.

The critical detail is receptor dynamics. GnRH receptors need time between stimulation events to recycle back to the cell surface. Pulsatile dosing, mimicking the hypothalamus's natural 60 to 120 minute rhythm, keeps receptors available and responsive. Constant or too-frequent exposure triggers receptor internalization and downregulation. LH and FSH production then drops, not rises. This is the pharmacologic principle behind GnRH agonist drugs like leuprolide (Lupron), which use continuous receptor occupancy to suppress testosterone in prostate cancer. Same molecule, opposite outcome, entirely determined by dosing pattern.

Subcutaneous injection extends the functional exposure window. IV half-life runs 2 to 10 minutes; SC terminal half-life stretches to roughly 20 to 40 minutes (Factrel FDA label). That slower absorption gives each bolus injection a more sustained receptor interaction than IV delivery.

Gonadorelin Benefits

  • Gonadorelin benefits center on preserving the HPG axis during exogenous testosterone use and restarting it afterward.
  • LH response is measurable within 15 to 30 minutes of the first injection, making it one of the fastest-confirming peptides on bloodwork (Factrel FDA label diagnostic protocol).
  • Testicular preservation on TRT. Community reports across 500+ r/trt and r/Testosterone threads consistently describe maintained testicular volume with nightly dosing protocols, a result that largely disappears at 2x/week frequency.
  • Prescribed through licensed compounding pharmacies when HCG is not. After the 2020 BPCIA reclassification pulled compounded HCG off shelves, gonadorelin became the most accessible alternative at $15 to $35 per month through licensed pharmacies.
  • Spermatogenesis induction in men with congenital hypogonadotropic hypogonadism (CHH). A 2025 retrospective cohort study by Zheng and colleagues [1] reported an 82.1% success rate with pulsatile pump delivery (75.8% on hCG/HMG, not a significant difference), with a mean 12.3 months to first sperm.
  • PCT utility for HPG axis restart. Post-cycle therapy protocols pair gonadorelin with SERMs like enclomiphene to restart endogenous LH, FSH, and testosterone after anabolic steroid suppression.

Gonadorelin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 5 key studies·FDA-approved

Pulsatile GnRH stimulates LH/FSH release from anterior pituitary.

Dosing studied: 10 mcg/90 min via pump (CHH pump studies); 100–200 mcg SC bolus (off-label TRT, community-derived)
Read the evidence (key study, limitations)

Mechanistically validated by FDA approval (diagnostic) and decades of CHH fertility data. A 2025 retrospective cohort study (n=155)[1] found pulsatile pump GnRH achieved spermatogenesis in 82.1% of CHH patients vs 75.8% with hCG/HMG (not significant), with a shorter mean time to first sperm (12.3 vs 14.7 months). No RCTs exist for bolus SC injection TRT co-administration.

Key Study

PMID 40119359: pulsatile GnRH vs hCG/HMG spermatogenesis, n=155, 2025; PMID 40800099: pump protocol outcomes, n=54, 2025

Limitations

All high-quality pump studies are in CHH (congenital hypogonadotropic hypogonadism), not exogenous TRT users. No head-to-head RCT of bolus SC gonadorelin vs HCG for TRT-associated testicular suppression. Off-label efficacy at 2–3×/week dosing is not clinically validated.

Community Experience
Moderate
3.2/5
Based on ~500+ r/trt threads

Widely adopted as post-2020 HCG compounding ban substitute.

Community dosing: 100 mcg SC nightly (most-recommended by experienced users); 20 mcg SC 6×/day (clinic protocol); 100–200 mcg 2–3×/week (clinic standard, widely considered subtherapeutic)
Read the reports (what users report 5, common issues 6)

At 2×/week, most users report minimal benefit; nightly 100 mcg or 20 mcg 6×/day protocols report more consistent testicular preservation. Response is highly variable. Sentiment mixed (3.2/5).

What users report (5)
  • Prevents testicular atrophy on TRT
  • More physiologic HPG axis stimulation than HCG
  • Lower cost than brand HCG ($15–35/month compounded)
  • Measurable LH spike within 30 min of injection
  • Available from licensed compounding pharmacies when HCG is not
Common issues (6)
  • Highly variable response: many users report no benefit at 2×/week
  • Extremely short half-life (2–4 min IV, ~20–40 min SC) makes bolus dosing suboptimal
  • Less proven than HCG for fertility/spermatogenesis preservation
  • Pulsatile pump, the gold standard, is impractical for most users
  • Paradoxical LH suppression risk if dosed too frequently or continuously
  • No consensus on ideal bolus frequency
Partially Aligned

Both science and community agree gonadorelin works via pulsatile GnRH mechanism. Diverge on practical bolus dosing: clinical trials use continuous pump delivery; community-prescribed 2–3×/week bolus lacks RCT backing and is considered subtherapeutic by most experts. Neither source has RCT data for TRT co-administration specifically.

Gonadorelin Dosage Guide

CommunityTRT clinic and community protocols: 100-200 mcg SC 2-3x/week alongside testosterone (r/trt, ExcelMale forum, clinic protocols).
LevelDose / InjectionFrequency
Beginner100 mcg
2x/weekTrack
Moderate200 mcg
2x/weekTrack
Aggressive200 mcg
3x/weekTrack
Note:

Reconstitution math: a 2 mg vial plus 2 mL bacteriostatic water gives you 1,000 mcg/mL. At 100 mcg per dose, that's 10 units on a U-100 insulin syringe. A 5 mg vial with 2 mL BAC water gives 2,500 mcg/mL, so 100 mcg equals 4 units.

The biggest beginner mistake is expecting results at 2x/week. Gonadorelin's subcutaneous half-life tops out around 40 minutes. Two injections per week leaves 3+ days of zero receptor stimulation between doses. If testicular preservation is the goal, nightly dosing at bedtime is the minimum frequency most experienced users and clinicians recommend.

Reconstituted vials last about 14 days refrigerated at 2 to 8 degrees Celsius. At 100 mcg/night from a 2 mg vial, you'll use 700 mcg per week, which means the full 2,000 mcg lasts roughly 20 days (2.86 weeks). That exceeds the 14-day reconstituted stability window, so roughly 30% of the vial may need to be discarded. Consider using a smaller vial or splitting reconstitution across two vials to avoid waste.

Use a 29 to 31 gauge, 1/2 inch insulin syringe. You'll barely feel the injection.

Cycling Protocol

On Period
8 weeks
Off Period
4 weeks

When used alongside TRT, many clinicians run continuously at 2x/week. For PCT, a typical course is 4-8 weeks.

Calculate your Gonadorelin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Gonadorelin Protocols by Goal

beginnerCommunityContinuous alongside TRT
Clinic-standard (low-frequency)
Wk Continuous
100 mcg · 2×/week (e.g., Sunday and Wednesday) · Subcutaneous

Expected: Partial LH stimulation; minimal testicular atrophy in some users. Response highly variable at this frequency.

Monitor: Check LH, FSH, total T at 6–8 weeks. If LH response is flat, consider frequency escalation or switching to nightly protocol.

How to Use Gonadorelin

  1. 1
    Step 1

    Gather supplies: gonadorelin vial (lyophilized), bacteriostatic water, alcohol swabs, insulin syringe (29 to 31 gauge, U-100).

  2. 2
    Reconstitute: add 2 mL of BAC water to a 2 mg vial

    Direct the stream down the side of the glass, not directly onto the powder. Swirl gently until fully dissolved. Don't shake. This gives you a concentration of 1,000 mcg per mL.

  3. 3
    Step 3

    Draw your dose: for 100 mcg, draw to the 10 unit mark on a U-100 syringe. For 200 mcg, draw to 20 units. For the 20 mcg micro-dose protocol, draw to 2 units.

  4. 4
    Clean injection site with an alcohol swab

    Abdominal fat (2 inches from the navel) or the front of the thigh are standard sites. Rotate locations each injection.

  5. 5
    Step 5

    Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly. Hold for 5 seconds before withdrawing.

  6. 6
    Step 6

    Timing: for TRT co-administration, inject at bedtime to align with natural nocturnal GnRH pulsatility. For PCT, morning dosing is typical. Avoid injecting on the same day as testosterone if running 2x/week frequency.

  7. 7
    Step 7

    Store reconstituted vial in the refrigerator (2 to 8 degrees Celsius). Discard after 14 days. Label the vial with the reconstitution date.

Alternative Routes

Subcutaneous injection

100–200 mcg SC bolus; terminal t½ ~20–40 min SC vs 2–10 min IV

Inject into abdominal fat or thigh. Rotate sites. SC provides slower absorption and longer receptor exposure vs IV.

Intravenous (IV)

100 mcg IV single dose (Factrel diagnostic protocol)

FDA-approved route for pituitary function testing. IV t½ 2–10 min. Not practical or appropriate for ongoing TRT co-administration.

Subcutaneous infusion pump

10–15 mcg per pulse every 90 min via programmable pump (total ~160–240 mcg/day)

Matches physiologic hypothalamic GnRH pulsatility. Used in CHH studies (PMID 40119359, 40800099). Matched hCG/HMG on spermatogenesis (82.1% vs 75.8%, not significant) and reached sperm sooner; no study compares it with bolus injection. Practical barrier: requires wearable infusion pump changed every 2–3 days.

Sublingual tablet

300 mcg sublingual (compounding pharmacy); oral/sublingual bioavailability unknown for gonadorelin

Gonadorelin is a 10-amino-acid peptide susceptible to oral proteolysis. Sublingual absorption may bypass some GI degradation but no human PK studies confirm adequate bioavailability. Use with caution; consider as last resort only.

Mixing your own vial? Use the Gonadorelin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Gonadorelin Stacking Protocols

Works With

Kisspeptin-10

Upstream HPG axis stimulation: kisspeptin acts on hypothalamic KNDy neurons to trigger endogenous GnRH release, potentially amplifying or complementing exogenous gonadorelin. Mechanistic rationale only; no RCT data for combination.

Kisspeptin-10 100–200 mcg SC 2–3×/week + Gonadorelin 100 mcg SC nightly

HCG

Not typically combined: HCG acts directly on Leydig cells while gonadorelin acts at pituitary. Some practitioners use short-term HCG loading followed by gonadorelin maintenance. Combining long-term is redundant and may interfere with HPG axis feedback.

Testosterone (TRT)

Primary co-administration use case. Gonadorelin added to TRT to maintain pituitary-testicular signaling, testicular volume, and fertility that exogenous testosterone suppresses.

Gonadorelin 100 mcg SC nightly alongside weekly/twice-weekly testosterone injections

Enclomiphene

PCT stack: enclomiphene (selective estrogen receptor modulator) blocks negative estrogen feedback at the pituitary to amplify FSH/LH release; gonadorelin directly stimulates gonadotropin release. Commonly combined in PCT protocols.

Gonadorelin 100 mcg SC daily + Enclomiphene 12.5 mg oral daily (PCT weeks 1–8)

Avoid

GnRH agonists (leuprolide, buserelin, nafarelin)

Continuous GnRH receptor occupancy from long-acting agonists causes receptor downregulation and LH/FSH suppression: the opposite of gonadorelin's intended effect. Combining would be counterproductive and potentially suppressive.

Do not combine
Oral contraceptives (estrogen-progestin)

Suppress pituitary gonadotropin secretion via negative HPG feedback, directly blunting gonadorelin's LH/FSH-stimulating effect. Listed as drug interaction in FDA label.

Digoxin

FDA label lists digoxin as blunting gonadotropin response to gonadorelin. Mechanism unclear.

Dopamine antagonists (phenothiazines, metoclopramide)

May blunt LH/FSH response to gonadorelin. Dopamine normally suppresses prolactin and modulates GnRH pulsatility; antagonists alter this balance. Listed in FDA label.

Estimated Cost

Brand Price
Factrel (gonadorelin HCl): discontinued in US. No brand equivalent currently marketed.
Compounded
Compounded via TRT clinic and 503A pharmacy: $36 for 5 mL vial at 200 mcg/mL (1,000 mcg total); $95 for 5 mL at 1,000 mcg/mL (5,000 mcg total). Clinic-managed pricing typically $15–35/month. Sublingual tabs (300 mcg): listed separately.

Pricing updated 2026-04-09

Gonadorelin Side Effects

Paradoxical LH suppression is the most serious risk with gonadorelin. Dosing too frequently or at too high a volume (above 200 mcg per day sustained) can cause GnRH receptor desensitization. The result is the opposite of the intended effect: LH and FSH decline, testosterone drops, and testicular atrophy accelerates. This isn't a theoretical concern. It's the exact mechanism that makes leuprolide an effective prostate cancer drug. If your labs show declining LH despite consistent gonadorelin use, receptor downregulation is the likely cause. Stop dosing for 3 to 5 days to allow receptor recovery.

Published side effects from the Factrel FDA label and clinical use data include headache, nausea, and lightheadedness. These are generally mild and occur most often after the first few injections. Flushing is reported within 30 minutes of injection in a subset of users.

Injection site reactions (redness, swelling, minor pain) occur at rates typical for any subcutaneous peptide. Rotating injection sites between abdominal fat and thigh reduces irritation.

Estradiol elevation is possible at weeks 6 to 8. As gonadorelin drives testosterone production through Leydig cells, some testosterone converts to estradiol via aromatase. Users with higher body fat or genetic aromatase activity may need an aromatase inhibitor. Monitor E2 levels if testosterone is rising and symptoms like water retention or nipple sensitivity appear.

Community reports from r/trt and ExcelMale forums flag highly variable individual response as the most common complaint, not side effects per se. Many users on 2x/week protocols report zero benefit, which is a dosing frequency issue rather than a safety issue.

Contraindications: hormone-dependent tumors (breast, prostate), pituitary apoplexy or known pituitary adenoma, pregnancy, and primary hypogonadism (gonadorelin stimulates the pituitary, so it won't help if the testes themselves can't respond). If you have primary hypogonadism, confirmed by raised baseline LH/FSH, this peptide is not indicated.

Stop use and consult a physician if you experience severe headache, visual disturbances, or signs of pituitary apoplexy.

Common Issues & Solutions

No testicular benefit at 2×/week: Frequency is almost always the issue: the 2–40 min half-life means each injection produces only a brief receptor pulse. Upgrade to nightly 100 mcg before assuming gonadorelin doesn't work.

LH spike confirmed on labs but testosterone not rising: This indicates primary (testicular) hypogonadism: gonadorelin works upstream, but if Leydig cells are impaired, LH stimulation won't produce testosterone. Gonadorelin is not indicated for primary hypogonadism.

Paradoxical LH decline with continued dosing: Receptor desensitization: especially at >200 mcg/day continuous dosing. Reduce frequency or take a 3–5 day break to allow receptor recovery. Note: at 2–3×/week, desensitization risk is minimal given the short half-life.

Short vial stability window: Reconstituted gonadorelin is stable only ~2 weeks at 2–8°C. Low-dose nightly protocols (100 mcg/night) use only 700 mcg/week: a 2 mg vial is consumed before stability window closes, but plan reconstitution accordingly.

PCT: testosterone not recovering by week 4: Add a SERM (enclomiphene or tamoxifen) to block pituitary estrogen feedback and amplify endogenous LH production. Gonadorelin alone may be insufficient if pituitary reserve is diminished after prolonged suppression.

Ask AI about this page

Ask AI for a second opinion on Gonadorelin dosing and side effects

Contraindications

  • Hormone-dependent tumors (breast, prostate)
  • Pituitary apoplexy or known pituitary adenoma
  • Pregnancy
  • Primary hypogonadism: pituitary stimulation won't help if testes can't respond

Drug Interactions

  • Androgens, estrogens, progestins: may blunt therapeutic effect
  • Oral contraceptives and digoxin: can suppress gonadotropin response
  • Phenothiazines and dopamine antagonists: may blunt LH/FSH response
  • Continuous GnRH receptor occupancy from long-acting agonists causes receptor downregulation and LH/FSH suppression: the opposite of gonadorelin's intended effect. Combining would be counterproductive and potentially suppressive.
  • Suppress pituitary gonadotropin secretion via negative HPG feedback, directly blunting gonadorelin's LH/FSH-stimulating effect. Listed as drug interaction in FDA label.

Product Quality

Recommended Monitoring

TestWhenTarget
LH (post-dose response test)Draw at 30 minutes post-injection on day 1 or week 1LH peak ≥2× pre-dose baseline; typical post-dose peak 4–12 mIU/mL
LH and FSH (baseline + follow-up)Baseline before starting; repeat at weeks 6–8LH: 1.4–12.8 mIU/mL; FSH: 1.5–12.4 mIU/mL
Total testosteroneBaseline; weeks 6–8; then every 3 monthsGoal: maintain or increase from suppressed baseline. PCT target: ≥400 ng/dL before discontinuing.
Estradiol (E2)At weeks 6–8 if testosterone is rising20–40 pg/mL (sensitive assay)
Semen analysisBaseline (if fertility is a goal); repeat at month 3–6Not listed
LH (post-dose response test)

Confirms pituitary GnRH receptor responsiveness. An LH rise of ≥2× baseline confirms pituitary is responsive to gonadorelin. Flat response may indicate pituitary damage or inadequate dose.

LH and FSH (baseline + follow-up)

Track whether pulsatile stimulation is maintaining LH/FSH levels. Also rules out primary hypogonadism if LH/FSH are elevated at baseline (indicating testes, not pituitary, are the failure point: gonadorelin will not help).

Total testosterone

Primary efficacy marker for TRT co-admin and PCT goals. Rising endogenous T confirms Leydig cell response.

Estradiol (E2)

Rising testosterone increases aromatase substrate, potentially elevating E2. May require aromatase inhibitor.

Semen analysis

Spermatogenesis depends on FSH-driven Sertoli cell support. Confirms whether gonadorelin is preserving/restoring sperm production.

Gonadorelin Before and After

First injection

Acute LH spike measurable within 15-30 minutes. No subjective effects yet.

Week 1-2

LH and FSH levels stabilizing with consistent pulsatile dosing.

Week 3-4

Testosterone levels start rising if pituitary-gonadal axis is intact.

Week 6-8

Full effect on testosterone, testicular volume, and spermatogenesis measurable on labs.

What to Expect

Day 1, first injection: LH peaks within 15 to 30 minutes and drops back to baseline in 2 to 4 hours. FSH takes longer to respond. No subjective effects yet. Some users draw a same-day LH lab at the 30 minute mark to confirm their pituitary is responding before committing to a full protocol. Mild flushing or lightheadedness can hit within 30 minutes. Transient headache in a minority.

Weeks 1 to 2: LH and FSH start stabilizing at higher basal levels with consistent pulsatile dosing. Leydig cell testosterone production activates in response. Most users don't feel anything yet. Some on nightly protocols notice slight scrotal fullness by end of week 2.

Weeks 3 to 4: Endogenous testosterone starts climbing if the pituitary-to-testicular axis is intact. Some users report libido improvement and subjective testicular fullness. The 2x/week crowd often reports nothing at this point; frequency is usually the limiting factor.

Weeks 6 to 8: This is where labs confirm whether the protocol is working. Testosterone, testicular volume, and sperm parameters should show maximum response. A 2025 retrospective pump study [2] found sperm in 27 of 34 men tested (79.4%), at a mean 6.48 ± 1.84 months. Users on nightly bolus protocols report consistent testicular size maintenance on semen analysis. Watch for estradiol creep as testosterone rises through aromatase conversion.

Months 3 to 6 (fertility focus): For men using gonadorelin specifically for fertility, PMID 40119359 reported a mean 12.3 months to first sperm with pulsatile pump. Bolus injection protocols likely run slower. Most fertility-focused users transition to HCG plus FSH under a reproductive endocrinologist at this stage if gonadorelin alone isn't cutting it.

Detailed Timeline: Science vs Community

Day 1: first injection
Science

LH peaks within 15–30 minutes of injection and returns to baseline within 2–4 hours. FSH rises more slowly. This is the mechanistic proof-of-concept.

Community

No subjective effects expected. Some users draw a same-day LH lab to confirm pituitary response before committing to protocol.

Week 1–2
Science

With consistent pulsatile dosing, LH and FSH levels begin stabilizing at higher basal levels. Testosterone production in Leydig cells activates in response to LH.

Community

Minimal noticeable change yet. Some users report slight scrotal fullness beginning at the end of week 2 with nightly dosing.

Week 3–4
Science

Endogenous testosterone measurably increases if pituitary-to-testicular axis is intact. LH and FSH stabilize with consistent pulsatile dosing.

Community

Some users report libido improvement and subjective testicular fullness. Variable response: 2×/week users often report nothing at this stage.

Week 6–8
Science

Testosterone, testicular volume (ultrasound-measurable), and sperm parameters should show maximum response at this point. A 2025 retrospective pump study (PMID 40800099): sperm in 27 of 34 men tested (79.4%), at a mean 6.48 ± 1.84 months.

Community

Experienced users on nightly protocol report consistent testicular size maintenance and improved fertility markers on semen analysis.

Month 3–6 (fertility focus)
Science

PMID 40119359: mean time to first sperm appearance was 12.3 months with pulsatile pump. Bolus injection protocols likely slower.

Community

Men using gonadorelin for fertility typically transition to HCG + FSH under fertility specialist guidance at this point if gonadorelin alone is insufficient.

Pharmacokinetics

Half-Life
24min
Bioavailability
SC: not precisely quantified in humans
Tmax
SC: ~15-30 min estimated from LH response curves
Data Confidence
high

Source: Factrel FDA label; SC terminal t½ ~20-40 min (IV t½ 2-10 min, but administration is SC)

Pharmacokinetics: Active Dose Over Time

t½ = 2-4 min (IV), ~10-40 min (SC)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
10
Molecular Weight
1,182.29 Da
Sequence
QHWSYGLRPG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 33515-09-2 (gonadorelin); 51952-41-1 (gonadorelin hydrochloride)PubChem 638793 (opens in a new tab)

Who Should Consider Gonadorelin

  • Men on TRT wanting to maintain fertility and testicular size
  • Athletes in post-cycle therapy after anabolic steroid use
  • Men with secondary hypogonadism seeking natural testosterone stimulation
  • Clinicians performing pituitary function diagnostics

Related Peptides

What Changed for Gonadorelin

  1. Regulatory

    Corrected Oct 10, 2026: gonadorelin is not on FDA's 503A bulk drug substance category lists, per the FDA 503A categories list updated May 14, 2026.

    What this does not mean: The page had said gonadorelin was in Category 1 on the 503A and 503B lists. No captured FDA list supports that, and no 503B list was checked.

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy

  2. Regulatory

    Corrected Oct 10, 2026: gonadorelin first gained FDA approval on Sep 30, 1982 (Factrel, NDA 018123), not in 1978, per Drugs@FDA.

    Before: No sourced US status record; the page said FDA-approved since 1978 After: US status FDA approved: Factrel NDA 018123 (Sep 30, 1982) and Lutrepulse Kit NDA 019687 (Oct 10, 1989), both discontinued

    What this does not mean: Factrel and Lutrepulse are both listed as discontinued in Drugs@FDA. Compounded gonadorelin is not an FDA-approved product.

    Source: Drugs@FDA record for Factrel (gonadorelin hydrochloride), NDA 018123 (openFDA): original approval Sep 30, 1982; products discontinued (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Comparison of outcomes between pulsatile gonadotropin releasing hormone and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism (Reprod Biol Endocrinol 2025) (opens in a new tab)(n=155)PubMed (opens in a new tab)PubMed
  2. [2]Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study (Transl Androl Urol 2025) (opens in a new tab)(n=54)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 3 months, refrigerated up to 2 years
After Reconstitution
Refrigerate at 2-8°C, use within 2 weeks
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

Depends heavily on how often you inject. At 2x/week, which is what most clinics prescribe; most experts say the results are minimal because gonadorelin's 2-4 minute half-life means it's gone before it can mimic natural pulsatile GnRH signaling. Protocols using nightly injections (100 mcg) or high-frequency dosing show much more consistent results. The compound works. LH response is measurable within 15-30 minutes, but twice-weekly dosing probably isn't enough.

Gonadorelin dosing varies by experience level. Beginners typically start at 100 mcg 2x/week, moderate users at 200 mcg 2x/week, and aggressive protocols use 200 mcg 3x/week.

Gonadorelin typically comes in 2mg or 5mg vials. Add 2mL of bacteriostatic water to the vial. Use the free calculator for exact syringe units based on your desired dose.

The half-life of Gonadorelin is 2-4 min (IV), ~10-40 min (SC). This determines how frequently you need to dose for consistent blood levels.

Paradoxical LH suppression is the most serious risk with gonadorelin. Dosing too frequently or at too high a volume (above 200 mcg per day sustained) can cause GnRH receptor desensitization. The result is the opposite of the intended effect: LH and FSH decline, testosterone drops, and testicular atrophy accelerates. This isn't a theoretical concern. It's the exact mechanism that makes leuprolide an effective prostate cancer drug. If your labs show declining LH despite consistent gonadorelin use, receptor downregulation is the likely cause. Stop dosing for 3 to 5 days to allow receptor recovery. Published side effects from the Factrel FDA label and clinical use data include headache, nausea, and lightheadedness. These are generally mild and occur most often after the first few injections. Flushing is reported within 30 minutes of injection in a subset of users. Injection site reactions (redness, swelling, minor pain) occur at rates typical for any subcutaneous peptide. Rotating injection sites between abdominal fat and thigh reduces irritation. Estradiol elevation is possible at weeks 6 to 8. As gonadorelin drives testosterone production through Leydig cells, some testosterone converts to estradiol via aromatase. Users with higher body fat or genetic aromatase activity may need an aromatase inhibitor. Monitor E2 levels if testosterone is rising and symptoms like water retention or nipple sensitivity appear. Community reports from r/trt and ExcelMale forums flag highly variable individual response as the most common complaint, not side effects per se. Many users on 2x/week protocols report zero benefit, which is a dosing frequency issue rather than a safety issue. Contraindications: hormone-dependent tumors (breast, prostate), pituitary apoplexy or known pituitary adenoma, pregnancy, and primary hypogonadism (gonadorelin stimulates the pituitary, so it won't help if the testes themselves can't respond). If you have primary hypogonadism, confirmed by raised baseline LH/FSH, this peptide is not indicated. Stop use and consult a physician if you experience severe headache, visual disturbances, or signs of pituitary apoplexy.